Filing Details
- Accession Number:
- 0000899243-21-031627
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-04 17:12:05
- Reporting Period:
- 2021-08-02
- Accepted Time:
- 2021-08-04 17:12:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1861560 | Nuvalent Inc. | NUVL | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1657434 | F. A. Andrew Hack | C/O Bain Capital Life Sciences Investors 200 Clarendon Street Boston MA 02116 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2021-08-02 | 2,693,014 | $0.00 | 2,693,014 | No | 4 | C | Indirect | See footnotes |
Class A Common Stock | Acquisiton | 2021-08-02 | 735,000 | $17.00 | 3,428,014 | No | 4 | P | Indirect | See footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnotes |
No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Series B Preferred Stock | Disposition | 2021-08-02 | 14,494,154 | $0.00 | 2,693,014 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- Represents securities held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").
- Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- Each share of the Issuer's Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.
- On August 2, 2021, BCLS II Investco purchased 735,000 shares of the Issuer's Class A Common Stock at a price of $17.00 per share in the Issuer's initial public offering.